Clinical Trial: A Randomized, Open-Label, Multicenter Phase III Clinical Study of SHR-A1811 Monotherapy Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab as Neoadjuvant Treatment in Previously Untreated Early or Locally Advanced HER2-Positive Breast Cancer (China)

China, Aug. 21 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Randomized, Open-Label, Multicenter Phase III Clinical Study of SHR-A1811 Monotherapy Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab as Neoadjuvant Treatment in Previously Untreated Early or Locally Advanced HER2-Positive Breast Cancer'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600130397

Registration Time: 2026/08/19

Type: Interventional study

Primary Sponsor: Fudan University Shanghai Cancer Center

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=293746

Published by HT Digital Content Services with permission from Health Daily Digest....